STOCK TITAN

Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) will host a conference call on February 11, 2021 at 8:00 a.m. ET to discuss its fourth quarter and year-end 2020 financial results. Management will outline financial expectations for 2021 and provide company updates. The presentation can be accessed via the investor section on Alkermes' website. A replay of the call will be available from February 11 to February 18, 2021. Alkermes is focused on developing innovative medicines in neuroscience and oncology, with a diverse product pipeline targeting various mental health and cancer disorders.

Positive
  • Upcoming conference call to discuss financial results and guidance for 2021.
  • Impressive pipeline focused on neuroscience and oncology.
Negative
  • None.

DUBLIN, Feb. 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 11, 2021 to discuss the company's fourth quarter and year-end 2020 financial results. Management will also discuss financial expectations for 2021 and provide an update on the company.

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers.

A replay of the conference call will be available from 11:00 a.m. ET (4:00 p.m. GMT) on Thursday, Feb. 11, 2021, through Thursday Feb. 18, 2021, and may be accessed by visiting Alkermes' website or by dialing +1 877 660 6853 for U.S. callers and +1 201 612 7415 for international callers. The replay access code is 13715619. 

About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Alex Braun
Investor Relations
+1 781 296 8493

 

Alkermes plc Logo (PRNewsfoto/Alkermes plc)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/alkermes-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-2020-financial-results-301222672.html

SOURCE Alkermes plc

FAQ

When will Alkermes announce its fourth quarter and year-end 2020 financial results?

Alkermes will announce its results on February 11, 2021.

What time is Alkermes' conference call on February 11, 2021?

The conference call is scheduled for 8:00 a.m. ET.

How can I access the replay of Alkermes' conference call?

The replay will be available from February 11 through February 18, 2021, on Alkermes' website or by dialing the provided access numbers.

What topics will be discussed during Alkermes' conference call?

The call will cover fourth quarter and year-end 2020 financial results and 2021 financial expectations.

What is Alkermes' focus in the biopharmaceutical market?

Alkermes focuses on developing medicines in the fields of neuroscience and oncology.

Alkermes Inc. plc

NASDAQ:ALKS

ALKS Rankings

ALKS Latest News

ALKS Stock Data

4.35B
169.22M
1.31%
112.23%
9.78%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
DUBLIN 4